Health Research Group Publications


Founded in 1971 by Sidney Wolfe, M.D. and Ralph Nader, Public Citizen’s Health Research Group promotes research-based, system-wide changes in health-care policy and drug safety. The work that we have done since 1995 is listed on this page in chronological order.

Public Citizen and 16 other groups sent a letter to members of the U.S. House of Representatives urging them to oppose S. 204, which is deceptively titled the “Right to Try Act of 2017” but should instead be called the “False Hope Act of 2017.”  The legislation, as amended and passed by the U.S. Senate on August 3, 2017, would put countless patients at risk by undermining important FDA safety rules related to the use and oversight of unapproved, experimental medications.

[Created on 9/5/2017]

Public Citizen submitted comments strongly urging the Occupational Safety and Health Administration (OSHA) not to: 1) finalize its proposal to rescind, for construction and shipyard workers, all ancillary provisions from its final 2017 beryllium rule; 2) delay for one year the deadline for compliance by construction and shipyard employers with the final beryllium standard; or 3) abdicate its duty to protect workers by refusing to enforce the final beryllium rule for construction and shipyard workers while this latest proposal is pending.

[Created on 8/28/2017]

Public Citizen and 17 other groups sent a letter to members of Congress urging them to oppose legislation that would most appropriately each be titled the “False Hope Act of 2017.” The legislation would put countless patients at risk by dramatically undermining the FDA’s role in ensuring that medical products are safe and effective before they become widely used.

[Created on 8/2/2017]

Public Citizen calls on the Office for Human Research Protections (OHRP) and the Department of Veterans Affairs (VA) Office of Research Oversight to immediately suspend the National Institutes of Health-funded Myocardial Ischemia and Transfusion (MINT) trial that is expected to involve 3,500 heart attack patients throughout the U.S. and Canada because of potentially serious ethical and regulatory violations.

[Created on 8/1/2017]

In testimony before a joint meeting of the Food and Drug Administration’s (FDA’s) Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees, Public Citizen urges the FDA to reject Intellipharmaceutics’ new version of oxycodone because, contrary to agency guidelines, the company has not conducted any human abuse potential studies of the drug to support a labeling claim that the drug deters intravenous abuse.

[Created on 7/26/2017]

In a letter to the Food and Drug Administration (FDA), Public Citizen urged the FDA not to approve liraglutide (Victoza) for the additional indication of reducing cardiovascular risk in type 2 diabetes patients because the clinical trial to support such approval failed to show any benefit in the 2,500 U.S. subjects in the trial. The study only showed a significant benefit in non-U.S. subjects.

[Created on 7/18/2017]

Ninety-one percent of the accountable care organizations (ACOs) that provide care to 9 million Medicare enrollees refuse to disclose their physician payment incentives, according to new research published today in the American Journal of Public Health. The study was conducted by researchers from Montefiore Medical Center in New York, City University of New York at Hunter College, and Public Citizen.

[Created on 7/12/2017]

Public Citizen sent a letter to members of Health Subcommittee of the U.S. House of Representatives’ Energy and Commerce Committee urging them to oppose draft legislation that would significantly expand marketing for unapproved uses of drugs and medical devices that have been approved or cleared by the FDA for at least one use. The legislation would undermine regulatory standards for ensuring that drugs and medical devices are safe and effective for each marketed use.

[Created on 7/11/2017]

Public Citizen opposes the Occupational Safety and Health Administration’s (OSHA’s) proposal to delay the deadline, from July 1 to December 1, 2017, for certain employers to submit injury and illness data electronically under its final rule entitled “Improve Tracking of Workplace Injuries and Illnesses”. The proposed postponement is unnecessary and will impede identification of workplace health and safety hazards.

[Created on 7/7/2017]

In an op-ed in RealClearHealth, Public Citizen harshly criticized a Trump administration proposal to eliminate the “ancillary provisions” of the Occupational Safety and Health Administration’s beryllium rule that would have extended specific new protections to construction and shipyard workers, including exposure assessments, personal protective equipment, medical surveillance and protected work areas.

[Created on 6/30/2017]